New drug combo shows promise for Hard-to-Treat cancers
NCT ID NCT00740805
First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times
Summary
This early-phase study tests a new drug (veliparib) combined with two chemotherapy drugs (cyclophosphamide and doxorubicin) in people with advanced solid tumors or non-Hodgkin lymphoma that cannot be removed by surgery or have spread. The main goal is to find the safest dose and understand side effects. About 81 adults will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANN ARBOR STAGE III NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Simple senior health quiz may predict chemo dangers
- New hope for kids with Hard-to-Treat cancers: targeted drug shows promise
- Cancer experts unite to personalize treatments in massive new study
- New drug targets tough childhood cancers with genetic flaws
- New drug shows promise for rare childhood cancers
- Scientists try out new tools to feel how hard tumors are